MannKind/$MNKD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
$MNKD
Sector
Primary listing
Employees
405
Headquarters
Website
MannKind Metrics
BasicAdvanced
$1.6B
49.63
$0.11
1.02
-
Price and volume
Market cap
$1.6B
Beta
1.02
52-week high
$7.39
52-week low
$3.38
Average daily volume
5.2M
Financial strength
Current ratio
2.495
Quick ratio
1.91
Long term debt to equity
-189.186
Total debt to equity
-277.161
Interest coverage (TTM)
2.23%
Profitability
EBITDA (TTM)
81.212
Gross margin (TTM)
74.91%
Net profit margin (TTM)
10.87%
Operating margin (TTM)
24.11%
Effective tax rate (TTM)
8.57%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
10.63%
Return on equity (TTM)
-23.36%
Valuation
Price to earnings (TTM)
49.63
Price to revenue (TTM)
5.173
Price to book
-29.89
Price to tangible book (TTM)
-26.47
Price to free cash flow (TTM)
54.221
Free cash flow yield (TTM)
1.84%
Free cash flow per share (TTM)
0.099
Growth
Revenue change (TTM)
21.48%
Earnings per share change (TTM)
149.32%
3-year revenue growth (CAGR)
66.30%
3-year earnings per share growth (CAGR)
-32.24%
10-year earnings per share growth (CAGR)
-23.92%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Bulls say / Bears say
Afrezza net sales climbed 13% year-over-year to $18.3 million in Q2 2025, underscoring growing commercial adoption of the inhaled insulin platform. (GuruFocus)
As of June 30, 2025, MannKind held $201.2 million in cash, cash equivalents, and investments, providing substantial runway to fund ongoing and upcoming clinical programs. (GuruFocus)
The company filed a supplemental BLA for Afrezza in pediatric patients with an FDA review decision expected in early Q4 2025, positioning MannKind to expand its addressable market to children and adolescents. (GuruFocus)
Shares dropped approximately 12% after Q2 results showed revenues of $76.5 million missed consensus estimates, reflecting investor concerns over growth execution. (Investing.com)
Collaborations and services revenue fell 12% and V-Go sales declined 8% in Q2 2025, highlighting the company’s reliance on a narrow product portfolio and potential volatility in non-core segments. (Investing.com)
Selling, general, and administrative expenses surged 31% year-over-year in Q2 2025, pressuring operating leverage as MannKind ramps up commercial and clinical infrastructure. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
MannKind News
AllArticlesVideos
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire1 day ago
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire3 weeks ago
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Benzinga3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.6B as of September 17, 2025.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 49.63 as of September 17, 2025.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.